Wednesday 24 July 2013

Stem cell survival after transplantation impacted by melatonin pre-treatment

Main Category: Stroke
Also Included In: Stem Cell Research;  Endocrinology
Article Date: 24 Jul 2013 - 1:00 PDT Current ratings for:
Stem cell survival after transplantation impacted by melatonin pre-treatment
not yet ratednot yet rated

When melatonin, a hormone secreted by the pineal gland, was used as a pre-treatment for mesenchymal stem cells (MSCs) prior to their transplantation into the brains of laboratory animals to repair damage from stroke, researchers in China found that the stem cells survived longer after transplantation. Previous studies had shown that 80 percent of transplanted MSCs died within 72 hours of transplantation. By contrast, the melatonin pre-treatment "greatly increased" cell survival, said the researchers.

The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line.*

The pineal gland is a small endocrine gland located in the center of the brain, but outside of the blood-brain barrier. The melatonin it secretes acts as a signal and forms part of the system that regulates the sleep-wake cycle by chemically causing drowsiness and lowering body temperature. Melatonin is also known to be a powerful antioxidant and has been used clinically to treat sleep disorders.

In this study, the researchers used a melatonin pre-treatment on MSCs they harvested from the laboratory animals that had been chemically modeled with ischemic brain injury (stroke). Previous studies had shown that MSCs "express" melatonin receptors M1 and M2.

"Mesenchymal cells can be harvested from self-donors (autologous) without ethical concerns," said study co-author Dr. Guo-Yuan Yang of the Neuroscience and Neuroengineering Research Center at the Shanghai Jiao Tong University in Shanghai, China. "Studies have shown that MSCs differentiate into various cells and can, upon transplantation, improve functional recovery after ischemic brain injury. In this study we used laboratory rats chemically modeled with stroke and tried to determine if pretreatment with melatonin would promote cell survival."

Researchers transplanted pre-treated MSCs into one group of brain injured rats and also used a control group of animals that received MSCs that were not pre-treated with melatonin.

Study results demonstrated that the melatonin pre-treated MSCs had "enhanced survival under oxidative stimulation by activating the Erk1/2 pathway" (extracellular signal-regulated kinases), a chain of proteins in the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell.

"Our study demonstrated increased survival of transplanted MSCs and revealed that the pre-treated MSCs reduced infarct volume and improved neurobehavioral outcomes for at least 14 days," said Dr. Yang.

The researchers noted that the impact of pre-treatment with melatonin was not MSC differentiation, and that development into mature brain cells was not an important factor in the beneficial effects derived from transplantation of either the untreated or the pre-treated cells. They suggested that the transplantation of MSCs pre-treated with melatonin may have a positive impact on the secretion of vascular endothelial growth factor (VEGF). VEGF is a signal protein produced by cells that stimulate vascular and blood vessel growth that can help restore the oxygen supply to tissues when blood circulation is inadequate.

"Our study demonstrated that melatonin pre-treatment promoted MSC survival in the laboratory setting and augmented the therapeutic efficiency of MSCs in the rat brain. The protective effect of melatonin is achieved by activation of the Erk1/2 pathway," they concluded. "This strategy of pre-treating stem cells may represent a safe approach for improving the beneficial effects of stem cell therapy for cerebral ischemia."

"It is important to identify factors that can impact on the survival of stem cells following their potential therapeutic use for a variety of neurological disorders", said Dr. Shinn-Zong Lin, professor of Neurosurgery and superintendent at the China Medical University Hospital, Beigang, Taiwan. "This study suggests that melatonin pretreatment could be a factor and its role should be explored further with other disease models and other cell types".

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our stroke section for the latest news on this subject.

Tang, Y.; Cai, B.; Yuan, F.; He, X.; Lin, X.; Wang, L.; Wang, Y.; Yang, G. Y. Melatonin pretreatment improves the survival and function of transplanted mesenchymal stem cells after focal cerebral ischemia. Cell Transplant. Appeared or available online: April 29, 2013.

The Coeditors-in-chief for CELL TRANSPLANTATION are at the Diabetes Research Institute, University of Miami Miller School of Medicine and Center for Neuropsychiatry, China Medical University Hospital, Beigang, Taiwan.

Cell Transplantation Center of Excellence for Aging and Brain Repair

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Cell Transplantation Center of Excellence for Agin. "Stem cell survival after transplantation impacted by melatonin pre-treatment." Medical News Today. MediLexicon, Intl., 24 Jul. 2013. Web.
24 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Stem cell survival after transplantation impacted by melatonin pre-treatment'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

No comments:

Post a Comment